Nasivin (Oxymetazoline Hydrochloride)

Oxymetazoline Hydrochloride, the active ingredient in Nasivin, is a alpha-adrenergic agonist presented as a nasal formulation for nasal use. It treats nasal congestion associated with the common cold, sinusitis, and allergic rhinitis in adults and children.

GNH USA supplies Nasivin as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oxymetazoline Hydrochloride is an alpha‑adrenergic agonist used to relieve nasal congestion in several common conditions.

- Common cold: reduces swelling of nasal mucosa to improve airflow. - Sinusitis: alleviates blockage of sinus passages, helping drainage. - Allergic rhinitis: diminishes nasal obstruction caused by allergic inflammation.

Oxymetazoline Hydrochloride may cause local and systemic adverse reactions, most of which are mild and transient.

Common Side Effects: - Nasal irritation or burning sensation. - Dryness of nasal passages. - Sneezing. - Headache. - Rebound congestion with prolonged use. - Transient taste disturbance.

Serious or Rare Side Effects: - Elevated blood pressure or hypertension. - Rapid heart rate (tachycardia) or arrhythmia. - Severe nasal ulceration or epistaxis. - Allergic reactions such as rash, itching, or swelling. - Anaphylaxis (rare but life‑threatening). - Central nervous system effects like dizziness or anxiety.

Before using Nasivin, consider the following safety measures.

- Duration of use: limit to no more than three consecutive days to avoid rebound congestion. - Age restrictions: avoid use in children under six years unless directed by a healthcare professional. - Cardiovascular disease: use with caution in patients with hypertension or heart disease. - Pregnancy and lactation: consult a physician; safety data are limited. - Concurrent nasal medications: do not combine with other topical decongestants. - Store at room temperature: keep in the original container, protect from moisture and direct heat.

Oxymetazoline may interact with other drugs, altering its safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other topical nasal decongestants: additive vasoconstriction may increase blood pressure.

Moderate Interactions (Monitor Closely): - Systemic sympathomimetics (e.g., pseudoephedrine): may enhance cardiovascular effects. - Antihypertensive agents: possible reduction in blood‑pressure‑lowering efficacy. - Tricyclic antidepressants: may increase risk of tachycardia. - Beta‑blockers: monitor for altered heart rate response. - Herbal stimulants (e.g., ephedra): potential additive sympathomimetic activity.